Trials / Completed
CompletedNCT03983538
Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
A Single Center Pilot Study Evaluating the Use of Mathematical Modeling to Predict Response to Neoadjuvant Anthracycline / Taxane Based Chemotherapy in Women With HER2 Negative Stage II and III Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- New Mexico Cancer Research Alliance · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant anthracycline / taxane based chemotherapy in patients with breast cancer.
Detailed description
This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant chemotherapy in patients with breast cancer. Chemotherapy will be protocol-approved chemotherapy regimen containing intravenous Doxorubicin (or Epirubicin), Cyclophosphamide, and Paclitaxel (or Docetaxel). Patients receive a protocol-approved chemotherapy regimen containing Doxorubicin (or Epirubicin), Cyclophosphamide, and Paclitaxel (or Docetaxel) based on the patient and/or physician preference. Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy. Following the completion of neoadjuvant chemotherapy, surgical approach and adjuvant radiation and endocrine therapy are left to the discretion of the treating physicians.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Mathematical modeling to predict response to chemotherapy | Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy. |
Timeline
- Start date
- 2015-06-02
- Primary completion
- 2018-01-28
- Completion
- 2018-01-28
- First posted
- 2019-06-12
- Last updated
- 2021-05-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03983538. Inclusion in this directory is not an endorsement.